

## Pharmablood

[View the current Pharmablood Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8211-Pharmablood.html)

(<http://www.bioportfolio.com/biocorporate/8211-Pharmablood.html>)

### Contact Details:

**2050 NE 163rd Street #201**

**North Miami Beach**

**Florida**

**33162**

**United States of America**

Tel: 305 9442544

Fax: 305 9445244

Email: [telemedical@pharmablood.com](mailto:telemedical@pharmablood.com)

PharmaBlood performs R&D of personalized medical treatment methods using as therapeutic agents autologous blood derivative compositions in cancer patients. PharmaBlood is a trademark of Telemedical Organization Inc used to identify the activity of the company in the field of research and development of blood derivatives as medical therapeutics.

Telemedical Organization Inc is an American company working in different fields of medical knowledge.

In cancer, PharmaBlood has assumed the following biological paradigm: 1) the presence in blood of molecules released by tumor cells or induced by malignant disease 2) the biological activity of these molecules over tumor cells or tumor stroma when they have been modified by physic-chemical or pharmacological procedures 3) the antigenic or positive/negative growth factors as mechanism of action for these modified molecules

As consequence, PharmaBlood has promoted studies about the procedures to modulate the releasing of tumor cell molecules to the patients' blood, the procedures to promote selected activities of these molecules over tumor biology through different modifications and the procedures to improve the involved mechanisms of action in medical practice.

Autologous blood as source of tumor associated molecules is the basis of the ParmaBlood personalized treatment that takes in consideration the individual differences among malignant tumors. The accessibility of blood in cancer patients allows a continuous updating of treatments using tumor released molecules as source of therapeutic agents acknowledging the frequent changes in tumor molecular components by spontaneous or therapeutically induced mutations.

The initial pre-clinical and clinical results are promising for the future development of PharmaBlood available treatments.

**Recent Publications by Pharmablood:**



- [Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative.](#)  
*INTRODUCTION: Advanced breast cancer patients, acquired-chemotherapy...20th July, 2007*  
PharmaBlood Inc, Research & Development Department, 2050 NE 163rd Street,- Breast Cancer Res Treat. 2006 Nov;100(2):149-60. Epub 2006 Jul 4. ([DOI Direct Link](#))
- [Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine.](#)  
*Tumor as source of tumor associated antigens (TAA) and sentinel lymph node...1st June, 2007*  
PharmaBlood Inc, Department of Research and Development, North Miami- Biologics. 2007 Jun;1(2):173-81.
- [Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative.](#)  
*INTRODUCTION: Advanced colon cancer patients, acquired-chemotherapy...3rd June, 2006*  
Department of Research & Development, PharmaBlood Inc, 2050 NE 163rd- Med Oncol. 2006;23(1):91-104.
- [Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients.](#)  
*PURPOSE: It has been reported that insulin increases the cytotoxic effect...17th March, 2004*  
Department of Medicine, School of Medicine, University of Uruguay,- Cancer Chemother Pharmacol. 2004 Mar;53(3):220-4. Epub 2003 Dec 4. ([DOI Direct Link](#))
- [Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer.](#)  
*In vitro exposure of malignant prostate cell lines to ascorbic...24th October, 2003*  
School of Medicine, University of Uruguay, Montevideo, Uruguay.- Med Oncol. 2003;20(1):45-52.
- [Antitumoral effect of a vaccination procedure with an autologous hemoderivative.](#)  
*Lately, the promising results obtained with autologous cancer vaccines are...17th October, 2003*  
School of Medicine, University of Uruguay, Uruguay.- Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60.

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

